The purpose of this research is to identify genetic and other patient factors that influence the ability of the medication clopidogrel (also known as Plavix) to block activation of platelets. This knowledge will help doctors identify patients who may not have a good response to clopidogrel.
Thank you for your interest, but this study is recruiting by invitation only.
North Dakota
Craig Lee
UNC Eshelman School of Pharmacy-Division of Pharmacotherapy and Experimental Therapeutics
Clinical or Medical
Observational
Genetics and Genetic Disorders
Heart and Circulation
23-0217
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
